

# **Expanded View Figures**

## Figure EV1. Binding activity and species specificity of ASC VHHs.

Lysates of HEK 293T cells transiently expressing HA-tagged VHH<sub>ASC</sub> (wild-type or point mutants), an unrelated control (VHH<sub>NP1</sub>) and the indicated bait proteins fused to Renilla luciferase were used to immunoprecipitate VHHs with immobilized anti-HA antibody. Renilla luciferase activity of the co-immunoprecipitated proteins was measured and normalized to the input luciferase. Data represents mean values  $\pm$  SEM from three independent experiments. \*\*\*\*P < 0.0001, One-way ANOVA, multiple comparison (Tukey test). TYD-KKK' indicates the triple mutant T57K, Y59K, and D62K.



Figure EV2. VHH<sub>ASC</sub> preserves endogenous inflammasome activation in human living cells.

- A, B Cell viability (CTB) assay on LPS-primed primary human macrophages that were left untreated, or pre-incubated with VHH<sub>ASC</sub> or mutVHH<sub>ASC</sub> (100  $\mu$ g ml<sup>-1</sup>), CRID3 (50  $\mu$ M) or VX-765 (50  $\mu$ M) for 30 min before being activated with (A) nigericin (10  $\mu$ M), or (B) PFO (30 ng ml<sup>-1</sup>) for 2 h. Data is from the experiments displayed in Fig 3A and B.
- C Human IL-1β (hIL-1β) concentrations in cell-free supernatants (left), and cell viability assay (right) of LPS-primed primary human macrophages that were incubated with VHH<sub>ASC</sub> or mutVHH<sub>ASC</sub> (100 μg ml<sup>-1</sup>), CRID3 (50 μM) or VX-765 (50 μM) for 30 min before being stimulated with 2.5 mM ATP.
- D hIL-1 $\beta$  concentrations in cell-free supernatants (top), and cell viability assay (bottom) of PMA-differentiated THP-1 cells treated with VHH<sub>ASC</sub> or mutVHH<sub>ASC</sub> (100  $\mu$ g ml<sup>-1</sup>), CRID3 (10  $\mu$ M) or VX-765 (50  $\mu$ M) for 30 min before 4.5 h stimulation with 250  $\mu$ g ml<sup>-1</sup> MSU crystals.
- E hIL-1β concentrations in cell-free supernatants (top), and cell viability assay (bottom) of LPS-primed primary human macrophages that were incubated with VHH<sub>ASC</sub> or mutVHH<sub>ASC</sub> (100  $\mu$ g ml<sup>-1</sup>), CRID3 (50  $\mu$ M) or VX-765 (50  $\mu$ M) for 30 min before being stimulated with 0.1  $\mu$ g ml<sup>-1</sup>/0.5  $\mu$ g ml<sup>-1</sup> mixture of LFn-BsaK and PA for 2 h.
- F hIL-1β concentrations in cell-free supernatants (top), and cell viability assay (bottom) of Pam3CysK4-primed (1  $\mu$ g ml<sup>-1</sup>) primary human CD14<sup>+</sup> monocytes that were incubated with VHH<sub>ASC</sub> or mutVHH<sub>ASC</sub> (100  $\mu$ g ml<sup>-1</sup>), or VX-765 (50  $\mu$ M) for 30 min before being stimulated with 1  $\mu$ g ml<sup>-1</sup> TcdA.
- G hIL-1 $\beta$  concentrations in cell-free supernatants (top), and cell viability assay (bottom) of keratinocyte cells (N-TERT) that were treated with VHH<sub>ASC</sub> or mutVHH<sub>ASC</sub> (100  $\mu$ g ml<sup>-1</sup>), or VX-765 (50  $\mu$ M), then directly stimulated with 30  $\mu$ M Val-boroPro (VbP) for 22 h.
- H hIL-1β concentrations in cell-free supernatants (top), and cell viability assay (bottom) of PMA-differentiated THP-1 cells treated with IFN $\gamma$  (500 U ml<sup>-1</sup>) for 16 h and that were incubated with VHH<sub>ASC</sub> or mutVHH<sub>ASC</sub> (100 µg ml<sup>-1</sup>), CRID3 (10 µM) or VX-765 (50 µM) for 30 min before 2 h stimulation with 1 µg ml<sup>-1</sup> poly(dA: dT) in complex with Lipofectamine 2000.

Data information: Data is representative of either two independent experiments, each run with one to two donors (A–C, E, F, 3 or 4 donors in total) or at least 3 independent experiments (D, G, H). Each symbol represents one donor or independent experiment.  ${}^{ns}P > 0.05$ ;  ${}^{*P} < 0.05$ ;  ${}^{**P} < 0.002$ ;  ${}^{****P} < 0.0002$ ;  ${}^{****P} < 0.0001$ , One-way ANOVA, multiple comparison (Tukey test). Data is displayed as floating bars with the max/min values and mean (thicker band).



### Figure EV3. VHH<sub>mASC</sub> is specific to ASC<sup>PYD</sup> but retains the same activity as VHH<sub>ASC</sub>.

- A Specificity of different single-domain antibodies (VHHs) probed by ELISA. Recombinant murine ASC as an eGFP fusion or eGFP alone (GFP-LPETG) as control, were coated onto ELISA plates at 1 µg ml<sup>-1</sup>/well. Wells were incubated with HA-tagged VHHs (100 nM), anti-HA-tag mouse mAb coupled to HRP, and the HRP substrate TMB. Binding was quantified by measuring the absorbance at 450 nm.
- B, C Lysates of HEK 293T cells transiently expressing HA-tagged VHH<sub>mASC</sub> or VHH<sub>ASC</sub> and the indicated bait proteins fused to Renilla luciferase were used to immunoprecipitate VHHs with immobilized anti-HA antibody. Renilla luciferase activity of the co-immunoprecipitated proteins was measured and normalized to the input luciferase. Data represents mean values ± SEM from three independent experiments.
- D, E Cell viability (CTB) assay on LPS-primed (200 ng ml<sup>-1</sup>) primary mouse BMDMs that were left untreated, or pre-incubated with VHH<sub>ASC</sub> or VHH<sub>mASC</sub> (100  $\mu$ g ml<sup>-1</sup>), CRID3 (50  $\mu$ M) or VX-765 (50  $\mu$ M) for 30 min before being activated with (D) nigericin (10  $\mu$ M), or (E) PFO (250 ng ml<sup>-1</sup>) for 2 h. Data is from the experiments displayed in Fig 3C and D. Data is displayed as floating bars with the max/min values and mean (thicker band).
- F Mouse IL-1 $\beta$  (mIL-1 $\beta$ ) concentrations in cell-free supernatants (left), and cell viability assay (right) of LPS-primed mouse BMDMs incubated with VHHs, CRID3 or VX-765, before stimulation with 0.1  $\mu$ g ml<sup>-1</sup>/0.5  $\mu$ g ml<sup>-1</sup> mixture of LFn-BsaK and PA for 2 h. Each symbol represents one mouse. Data is displayed as floating bars with the max/min values and mean (thicker band).

Data information:  $^{ns}P > 0.05$ ; \*\*\*P < 0.001; \*\*\*\*P < 0.0001, Two-way (A, C) or One-way (B, D–F) ANOVA, multiple comparison (Tukey test).



## Figure EV4. Contribution of GSDMD in the effect of VHHASC on the internalization of VHH<sub>ASC</sub> in cells stimulated with PFO or nigericin.

THP-1 cells expressing a Dox-inducible CRISPR-Cas9 cassette targeting GSDMD gene were left untreated (-) or treated with 1  $\mu$ g ml<sup>-1</sup> Dox for one or two cycles of 72 h (1×, or 2× respectively).

A, B Confocal microscopy images of GSDMD competent (–Dox) or GSDMD-KO (+Dox) cells primed with PMA and that were either left untreated or treated with (A) nigericin (10 μM) or (B) PFO (30 ng ml<sup>-1</sup>) for the indicated periods of time and in the presence of AlexaFluor647-labeled VHH<sub>ASC</sub> (VHH<sub>ASC</sub>-AF647, 10 μg ml<sup>-1</sup>, blue) and propidium iodide (PI, 3.33 μg ml<sup>-1</sup>, red). White arrows indicate of cells with intracellular VHH<sub>ASC</sub>-AF647 signal. Dashed circles define boundaries of representative cells. Data is from one representative out of three independent experiments. Scale bar: 10 μm. Also see Movie EV1.



#### Figure EV5. VHH<sub>ASC</sub> disrupts post-pyroptotic ASC specks.

- A PMA-differentiated (50 ng ml<sup>-1</sup>) THP-1 ASC-GFP cells were treated with IFN $\gamma$  (500 U ml<sup>-1</sup>) for 16 h. Then, cells were pre-incubated with VHH<sub>ASC</sub> (100 µg ml<sup>-1</sup>), or VX-765 (50 µM) for 30 min before being activated with poly(dA:dT) (dA:dT, 1 µg ml<sup>-1</sup>) and imaged live with a CellDiscoverer 7 microscope as described in Fig 4 over 3 h. Data is a graphic representation of the percent of specking cells over time. Maximal intensity projections from Z-stacks were generated for each image set (8 images per condition) before the number of cells and specks per field were calculated using CellProfiler. Also see Movie EV3.
- B Flow cytometric quantification (left), or western-blot (right, following DSS cross-linking) assessement of GFP<sup>+</sup> specks in the supernatants of cells pre-treated with VHH<sub>ASC</sub> or VX-765 and then activated with poly(dA:dT) for 3.5 h. Data in left panel is displayed as floating bars with the max/min values and mean (thicker band).
- C Flow cytometric quantification or western-blotting of GFP+ specks released by PMA-differentiated THP-1 ASC-GFP cells pre-incubated with VHH<sub>ASC</sub> (100  $\mu$ g ml<sup>-1</sup>), or VX-765 (50  $\mu$ M) for 30 min before stimulation with LFn-MxiH/PA (100 ng ml<sup>-1</sup>/1  $\mu$ g ml<sup>-1</sup>) for 3 h and imaged live with a CellDiscoverer 7 microscope. Also see Movie EV4.
- D GFP<sup>+</sup> specks detected by flow cytometry (left) or western-blot (right, following DSS cross-linking) in the supernatants of cells pre-treated with VHH<sub>ASC</sub> or VX-765 and then activated with LFn-MxiH/PA for 3.5 h. Data in left panel is displayed as floating bars with the max/min values and mean (thicker band).
- E PMA-differentiated THP-1 ASC-GFP cells were pre-incubated with VHH<sub>ASC</sub> (100  $\mu$ g ml<sup>-1</sup>), or VX-765 (50  $\mu$ M) for 30 min before stimulation with MSU crystals (250  $\mu$ g ml<sup>-1</sup>) for 4.5 h and imaged live with a CellDiscoverer 7 microscope. Imaging and quantifications were done as in (A). Also see Movie EV5.

Source data are available online for this figure.